<?xml version="1.0" encoding="UTF-8"?>
<p id="Par6">The drugs that are currently being used and tested in COVID-19 treatment are mostly the ones used by patients with rheumatic diseases. Thus, the rheumatologists participate in the multidisciplinary management of COVID-19 patients, as well. On the other hand, immunosuppressants put patients with rheumatic diseases in a vulnerable group in this pandemic. Thus, making effective and accurate decisions about management strategies regarding these patients is critical, and these should be based on the currently available scientific evidence as much as possible.</p>
